Blue Bell’s Neos Therapeutics Competing for Share of $10 Billion ADHD Market

By

NEOS

Blue Bell’s Neos Therapeutics is starting to compete for a share of the $10 billion ADHD market with last week’s launch of its first branded product for the treatment of the disorder, writes John George for the Philadelphia Business Journal.

Vipin K. Garg, President and CEO of Neos, indicated that ADHD is most commonly treated with either an amphetamine or methylphenidate, available in extended-release capsules, patches, liquids, orally disintegrating tablets, or chewable drug-delivery formats.

Neos’ Adzenys XR-ODT, an amphetamine product approved by the FDA in late January, is the first ADHD drug on the market which is both extended release and orally disintegrating.

ADHD affects close to five percent of children and 2.5 percent of adults in the United States. In surveys of doctors, orally disintegrating tablets are ranked as their next choice after regular capsules or tablets.

The Texas-based company, which has its commercial sales headquarters in Blue Bell, also expects to launch Cotempla XR-ODT, its second extended-release product sometime next year.

“We’re not saying we are going to get 13 percent of market, if we got half that, it would be phenomenal,” said Garg. “We hope to get as much of the market as we can. Each share point equals $125 million, so if you can get two percent, you are a $250 million company.”

Read more about Neos Therapeutics at Philadelphia Business Journal by clicking here.

Read more of MONTCO Today’s coverage of Neos Therapeutics’ ADHD drug by clicking here.

Stay Connected, Stay Informed

Subscribe for great stories in your community!

"*" indicates required fields

Hidden
MT Yes
This field is for validation purposes and should be left unchanged.
Advertisement